Articles

Many women whose breast cancer expresses the hormones estrogen or progesterone are recommended a daily intake of tamoxifen or aromatase inhibitors for 5 years. Read More ›

Patients receiving chemotherapy often experience chemotherapy-induced peripheral neuropathy that for up to 40% of patients may persist for months or years following chemotherapy treatments. Read More ›

A recently published study shows that when treating prostate cancer, intermittent androgen deprivation therapy is not as beneficial as continuous androgen deprivation. Read More ›

New retrospective study results show that amiodarone, a widely used arrhythmia medication, may increase the risk of developing cancer. Read More ›

On average, African American men experience a longer wait time between prostate cancer diagnosis and treatment than do Caucasian men. Read More ›

The increased cancer survival population will offer distinctive healthcare challenges in the future. Read More ›

Breast cancer mortality may also be greater for those patients taking combined hormone therapy. Read More ›

New guidelines related to the care of multiple myeloma patients not participating in clinical trials were recently published. Read More ›

Men with Lynch syndrome not only face a higher risk of prostate cancer, but they also seem to acquire the disease at a younger age, according to new research. Read More ›

OnPART can predict 6 common side effects of dose-dense doxorubicin plus cyclophosphamide plus paclitaxel chemotherapy in patients with breast cancer with a high degree of accuracy, according to the results of a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium. Read More ›